siponimod 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5326 1230487-009

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • siponimod
  • siponimod fumaric acid
  • mayzent
  • NVP-BAF312-NX
  • BAF-312
Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator. Siponimod binds with high affinity to S1P receptors 1 and 5. Siponimod blocks the capacity of lymphocytes to egress from lymph nodes, reducing the number of lymphocytes in peripheral blood. The mechanism by which siponimod exerts therapeutic effects in multiple sclerosis is unknown, but may involve reduction of lymphocyte migration into the central nervous system.
  • Molecular weight: 516.61
  • Formula: C29H35F3N2O3
  • CLOGP: 5.85
  • LIPINSKI: 1
  • HAC: 5
  • HDO: 1
  • TPSA: 62.13
  • ALOGS: -6.21
  • ROTB: 10

  • Status: ONP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Jan. 13, 2020 EMA Novartis Europharm Limited
March 26, 2019 FDA NOVARTIS PHARMS CORP
June 29, 2020 PMDA Novartis Pharma K.K.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lymphocyte count decreased 223.53 29.03 78 3171 26229 50575646
Multiple sclerosis relapse 169.66 29.03 73 3176 42891 50558984
Lymphopenia 104.99 29.03 39 3210 15582 50586293
Gait disturbance 89.23 29.03 75 3174 149930 50451945
Expanded disability status scale score increased 75.36 29.03 14 3235 356 50601519
Headache 58.76 29.03 111 3138 506424 50095451
Basal cell carcinoma 55.57 29.03 28 3221 23328 50578547
Multiple sclerosis 44.19 29.03 23 3226 20470 50581405
Fatigue 43.86 29.03 121 3128 707480 49894395
Dizziness 42.61 29.03 78 3171 346291 50255584
Balance disorder 41.22 29.03 35 3214 70555 50531320
Vision blurred 39.91 29.03 36 3213 78611 50523264
White blood cell count decreased 38.07 29.03 42 3207 116680 50485195
Product dose omission issue 35.68 29.03 51 3198 183787 50418088
Feeling abnormal 35.58 29.03 42 3207 125450 50476425
COVID-19 35.45 29.03 27 3222 46635 50555240
Heart rate decreased 34.25 29.03 24 3225 36473 50565402
Visual impairment 30.27 29.03 29 3220 68246 50533629
Urinary tract infection 29.43 29.03 52 3197 223968 50377907
Drug titration error 29.35 29.03 7 3242 603 50601272

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Multiple sclerosis relapse 116.02 40.02 34 1064 11385 29562044
Lymphocyte count decreased 47.50 40.02 20 1078 19251 29554178
Lymphopenia 43.49 40.02 17 1081 13516 29559913

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Lymphocyte count decreased 143.55 35.36 57 2732 40642 64455301
Basal cell carcinoma 111.50 35.36 44 2745 30794 64465149
Multiple sclerosis relapse 92.87 35.36 42 2747 41093 64454850
Lymphopenia 80.25 35.36 33 2756 25624 64470319
Gait disturbance 68.98 35.36 58 2731 172097 64323846
Balance disorder 62.29 35.36 41 2748 83885 64412058
Fatigue 59.27 35.36 111 2678 748619 63747324
Headache 54.15 35.36 88 2701 529379 63966564
Multiple sclerosis 48.02 35.36 21 2768 18920 64477023
Expanded disability status scale score increased 45.80 35.36 9 2780 465 64495478
Urinary tract infection 43.99 35.36 52 2737 231544 64264399
Movement disorder 41.93 35.36 20 2769 21980 64473963
Dizziness 37.89 35.36 67 2722 430096 64065847
Central nervous system lesion 36.20 35.36 15 2774 11834 64484109

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L04AA42 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSUPPRESSANTS
IMMUNOSUPPRESSANTS
Selective immunosuppressants
MeSH PA D007155 Immunologic Factors
MeSH PA D007166 Immunosuppressive Agents
MeSH PA D000081243 Sphingosine 1 Phosphate Receptor Modulators

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Relapsing remitting multiple sclerosis indication 426373005 DOID:2378
Sick sinus syndrome contraindication 36083008 DOID:13884
Atrioventricular block contraindication 233917008 DOID:0050820




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 3.28 acidic
pKa2 7.69 Basic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 0.25MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL 8492441 Nov. 30, 2030 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
EQ 1MG BASE MAYZENT NOVARTIS N209884 Aug. 24, 2021 RX TABLET ORAL 8492441 Nov. 30, 2030 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE
EQ 2MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL 8492441 Nov. 30, 2030 A METHOD OF TREATING MULTIPLE SCLEROSIS BY ADMINISTERING SIPONIMOD USING A TITRATION SCHEME TO REACH A MAINTENANCE DOSE

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
EQ 0.25MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL March 26, 2024 NEW CHEMICAL ENTITY
EQ 1MG BASE MAYZENT NOVARTIS N209884 Aug. 24, 2021 RX TABLET ORAL March 26, 2024 NEW CHEMICAL ENTITY
EQ 2MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL March 26, 2024 NEW CHEMICAL ENTITY
EQ 0.25MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL March 1, 2025 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130
EQ 1MG BASE MAYZENT NOVARTIS N209884 Aug. 24, 2021 RX TABLET ORAL March 1, 2025 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130
EQ 2MG BASE MAYZENT NOVARTIS N209884 March 26, 2019 RX TABLET ORAL March 1, 2025 REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sphingosine 1-phosphate receptor 1 GPCR MODULATOR EC50 9.41 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 5 GPCR MODULATOR EC50 9.01 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 4 GPCR MODULATOR EC50 6.13 SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 3 GPCR MODULATOR EC50 3 SCIENTIFIC LITERATURE
Sphingosine 1-phosphate receptor 2 GPCR MODULATOR EC50 4 SCIENTIFIC LITERATURE

External reference:

IDSource
RR6P8L282I UNII
C3657824 UMLSCUI
J8C PDB_CHEM_ID
CHEMBL2336071 ChEMBL_ID
44599207 PUBCHEM_CID
DB12371 DRUGBANK_ID
CHEMBL4298150 ChEMBL_ID
D11072 KEGG_DRUG
9289 IUPHAR_LIGAND_ID
2121085 RXNORM
312581 MMSL
36617 MMSL
d09219 MMSL
786997005 SNOMEDCT_US
787019001 SNOMEDCT_US
4038283 VANDF
017942 NDDF
017943 NDDF
C578989 MESH_SUPPLEMENTAL_RECORD_UI
9491 INN_ID
1230487-00-9 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
MAYZENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0979 TABLET, FILM COATED 0.25 mg ORAL NDA 29 sections
MAYZENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0979 TABLET, FILM COATED 0.25 mg ORAL NDA 29 sections
MAYZENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0986 TABLET, FILM COATED 2 mg ORAL NDA 29 sections
MAYZENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-0986 TABLET, FILM COATED 2 mg ORAL NDA 29 sections
MAYZENT HUMAN PRESCRIPTION DRUG LABEL 1 0078-1014 TABLET, FILM COATED 1 mg ORAL NDA 29 sections